Glenmark Pharmaceuticals has been ranked number 1 in dermatologists’ prescriptions in the protective emollients category and for prescribing derma therapy. This is based on the IQVIA medical audit for MAT Dec 2023 (as per Projected Prescriptions) in India. Projected prescriptions figures are for the period from Jan 2023 to Dec 2023.
Key products in Glenmark’s dermatology portfolio include Episoft, Candid Dusting Powder, Momate, Canditral SB, La Shield, Scalpe+, Tacroz ointment, etc. The company’s flagship brand Candid Powder delivered revenue growth of 20 per cent for Q3 FY24. La Shield portfolio delivered YoY revenue growth of 20 per cent, while Scalpe+ portfolio witnessed YoY revenue growth of 12.2 per cent in Q3 FY24.
As per reports, Glenmark outperforms the market with a dermatology value growth of 9.9 per cent and a market share of 7.49 per cent in the dermatology sector as per MAT Dec 2023.
Key products in Glenmark’s dermatology portfolio include Episoft, Candid Dusting Powder, Momate, Canditral SB, La Shield, Scalpe+, Tacroz ointment, etc. The company’s flagship brand Candid Powder delivered revenue growth of 20 per cent for Q3 FY24. La Shield portfolio delivered YoY revenue growth of 20 per cent, while Scalpe+ portfolio witnessed YoY revenue growth of 12.2 per cent in Q3 FY24.
As per reports, Glenmark outperforms the market with a dermatology value growth of 9.9 per cent and a market share of 7.49 per cent in the dermatology sector as per MAT Dec 2023.
The post appeared first on .